Addition of Inflammation-related Biomarkers to the CAIDE Model for Risk Prediction of All-cause Dementia, Alzheimer's Disease and Vascular Dementia in a Prospective Study

Overview

Journal Immun Ageing

Publisher Biomed Central

Specialty Geriatrics

Date 2024 Apr 3

PMID 38570813

Authors

Kira Trares

Manuel Wiesenfarth

Hannah Stocker

Laura Perna

Agnese Petrera

Stefanie M Hauck

Konrad Beyreuther

Hermann Brenner

Ben Schottker

Affiliations

Soon will be listed here.

Abstract

Background: It is of interest whether inflammatory biomarkers can improve dementia prediction models, such as the widely used Cardiovascular Risk Factors, Aging and Dementia (CAIDE) model.

Methods: The Olink Target 96 Inflammation panel was assessed in a nested case-cohort design within a large, population-based German cohort study (n = 9940; age-range: 50-75 years). All study participants who developed dementia over 20 years of follow-up and had complete CAIDE variable data (n = 562, including 173 Alzheimer's disease (AD) and 199 vascular dementia (VD) cases) as well as n = 1,356 controls were selected for measurements. 69 inflammation-related biomarkers were eligible for use. LASSO logistic regression and bootstrapping were utilized to select relevant biomarkers and determine areas under the curve (AUCs).

Results: The CAIDE model 2 (including Apolipoprotein E (APOE) ε4 carrier status) predicted all-cause dementia, AD, and VD better than CAIDE model 1 (without APOE ε4) with AUCs of 0.725, 0.752 and 0.707, respectively. Although 20, 7, and 4 inflammation-related biomarkers were selected by LASSO regression to improve CAIDE model 2, the AUCs did not increase markedly. CAIDE models 1 and 2 generally performed better in mid-life (50-64 years) than in late-life (65-75 years) sub-samples of our cohort, but again, inflammation-related biomarkers did not improve their predictive abilities.

Conclusions: Despite a lack of improvement in dementia risk prediction, the selected inflammation-related biomarkers were significantly associated with dementia outcomes and may serve as a starting point to further elucidate the pathogenesis of dementia.

References

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

Torres S, Alexander A, OBryant S, Medina L . Cognition and the Predictive Utility of Three Risk Scores in an Ethnically Diverse Sample. J Alzheimers Dis. 2020; 75(3):1049-1059. PMC: 8273928. DOI: 10.3233/JAD-191284. View

Tang E, Harrison S, Errington L, Gordon M, Visser P, Novak G . Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review. PLoS One. 2015; 10(9):e0136181. PMC: 4559315. DOI: 10.1371/journal.pone.0136181. View

Stephan B, Pakpahan E, Siervo M, Licher S, Muniz-Terrera G, Mohan D . Prediction of dementia risk in low-income and middle-income countries (the 10/66 Study): an independent external validation of existing models. Lancet Glob Health. 2020; 8(4):e524-e535. PMC: 7090906. DOI: 10.1016/S2214-109X(20)30062-0. View

Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J . Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006; 5(9):735-41. DOI: 10.1016/S1474-4422(06)70537-3. View

Stocker H, Perna L, Weigl K, Mollers T, Schottker B, Thomsen H . Prediction of clinical diagnosis of Alzheimer's disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years. Mol Psychiatry. 2020; 26(10):5812-5822. PMC: 8758470. DOI: 10.1038/s41380-020-0764-y. View

Alexander G, Emerson S, Kesselheim A . Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. JAMA. 2021; 325(17):1717-1718. DOI: 10.1001/jama.2021.3854. View

Heinze G, Wallisch C, Dunkler D . Variable selection - A review and recommendations for the practicing statistician. Biom J. 2018; 60(3):431-449. PMC: 5969114. DOI: 10.1002/bimj.201700067. View

Kivimaki M, Livingston G, Singh-Manoux A, Mars N, Lindbohm J, Pentti J . Estimating Dementia Risk Using Multifactorial Prediction Models. JAMA Netw Open. 2023; 6(6):e2318132. PMC: 10265307. DOI: 10.1001/jamanetworkopen.2023.18132. View

10.

Sauerbrei W, Perperoglou A, Schmid M, Abrahamowicz M, Becher H, Binder H . State of the art in selection of variables and functional forms in multivariable analysis-outstanding issues. Diagn Progn Res. 2020; 4:3. PMC: 7114804. DOI: 10.1186/s41512-020-00074-3. View

11.

Kivipelto M, Helkala E, Hanninen T, Laakso M, Hallikainen M, Alhainen K . Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001; 56(12):1683-9. DOI: 10.1212/wnl.56.12.1683. View

12.

Mahase E . Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns. BMJ. 2021; 375:n3127. DOI: 10.1136/bmj.n3127. View

13.

Perneczky R, Jessen F, Grimmer T, Levin J, Floel A, Peters O . Anti-amyloid antibody therapies in Alzheimer's disease. Brain. 2023; 146(3):842-849. DOI: 10.1093/brain/awad005. View

14.

Exalto L, Quesenberry C, Barnes D, Kivipelto M, Biessels G, Whitmer R . Midlife risk score for the prediction of dementia four decades later. Alzheimers Dement. 2013; 10(5):562-70. DOI: 10.1016/j.jalz.2013.05.1772. View

15.

Stephan B, Kurth T, Matthews F, Brayne C, Dufouil C . Dementia risk prediction in the population: are screening models accurate?. Nat Rev Neurol. 2010; 6(6):318-26. DOI: 10.1038/nrneurol.2010.54. View

16.

Harrison S, de Craen A, Kerse N, Teh R, Granic A, Davies K . Predicting Risk of Cognitive Decline in Very Old Adults Using Three Models: The Framingham Stroke Risk Profile; the Cardiovascular Risk Factors, Aging, and Dementia Model; and Oxi-Inflammatory Biomarkers. J Am Geriatr Soc. 2016; 65(2):381-389. DOI: 10.1111/jgs.14532. View

17.

Kinney J, Bemiller S, Murtishaw A, Leisgang A, Salazar A, Lamb B . Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y). 2018; 4:575-590. PMC: 6214864. DOI: 10.1016/j.trci.2018.06.014. View

18.

Royston P, Sauerbrei W . Building multivariable regression models with continuous covariates in clinical epidemiology--with an emphasis on fractional polynomials. Methods Inf Med. 2005; 44(4):561-71. View

19.

Hou X, Feng L, Zhang C, Cao X, Tan L, Yu J . Models for predicting risk of dementia: a systematic review. J Neurol Neurosurg Psychiatry. 2018; 90(4):373-379. DOI: 10.1136/jnnp-2018-318212. View

20.

Cummings J . Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics. Drugs. 2023; 83(7):569-576. PMC: 10195708. DOI: 10.1007/s40265-023-01858-9. View